Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 50,000 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 50,000 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $79,321,592. The trade was a 6.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, July 1st, Nello Mainolfi sold 80,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00.
• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $81.18, for a total transaction of $2,435,400.00.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $119.24 on Wednesday. The company has a market capitalization of $9.81 billion, a price-to-earnings ratio of -33.40 and a beta of 1.95. The company’s 50 day simple moving average is $88.60 and its 200 day simple moving average is $83.58. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. Kymera Therapeutics’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.82) EPS. Equities analysts expect that Kymera Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

Institutional Trading of Kymera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC lifted its position in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Kymera Therapeutics by 27.5% during the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after acquiring an additional 98 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics during the 4th quarter valued at $63,000.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Morgan Stanley reiterated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. BTIG Research reaffirmed a “buy” rating and set a $134.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, June 25th. Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $110.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $121.41.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.